Can platinib make tumors smaller?

Platinib, as a targeted drug targeting RET mutations, has shown remarkable results in cancer treatment in recent years. Platinib is an oral, potent and highly selective RET inhibitor. It can precisely target RET gene mutations and inhibit the growth and spread of tumor cells. This highly selective mechanism of action gives platinib significant advantages in the treatment of RET-positive cancers.

Multiple clinical trials have confirmed that platinib can make tumors smaller. For example, in a clinical trial, patients' serum tumor marker calcitonin was reduced by more than 90% after treatment with platinib, and target lesions were reduced by 19% after only 28 days. In another study, 78% of patients with RET fusion-positive non-small cell lung cancer experienced substantial tumor shrinkage after treatment with platinib. These data provide strong evidence for the efficacy of platinib in shrinking tumors.

In addition to clinical trial data, actual application cases also show that platinib can indeed shrink tumors. After receiving platinib treatment, some patients not only experienced a significant reduction in tumor volume, but also experienced significant improvement in clinical symptoms. These practical application effects further confirm the effectiveness of Platinib in shrinking tumors.

It is important to note that while platinib is excellent at shrinking tumors, efficacy may vary between patients. In addition, cancer treatment usually requires comprehensive treatments, including surgery, radiotherapy, chemotherapy, etc. Therefore, when using platinib, a personalized treatment plan should be developed based on the patient's specific situation.